Kayne Anderson Rudnick Investment Management
HRMY icon

Kayne Anderson Rudnick Investment Management’s Harmony Biosciences HRMY Stock Holding History

Kayne Anderson Rudnick Investment Management’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-33
Closed -$2K – 635
2022
Q1 		$2K Buy
+33
New +$1.35K ﹤0.01% 593

Other funds holding HRMY

VM
Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management's HRMY Position: Q2 2022 in Review

Kayne Anderson Rudnick Investment Management sold out of Harmony Biosciences (HRMY) in Q2 2022, closing a stake of 33 shares — an estimated $2K sold.

Kayne Anderson Rudnick Investment Management first reported a position in HRMY in Q1 2022 and held it in 1 quarter. The position peaked at $2K in Q1 2022. 183 funds tracked by Wall St. Rank hold HRMY as of Q2 2022.

  • Kayne Anderson Rudnick Investment Management reported no remaining Harmony Biosciences position as of Q2 2022 after selling out during the quarter.
  • Kayne Anderson Rudnick Investment Management sold 33 Harmony Biosciences shares in Q2 2022, an estimated $2K.
  • Kayne Anderson Rudnick Investment Management first reported a position in Harmony Biosciences in Q1 2022 and held it in 1 quarter.
  • Kayne Anderson Rudnick Investment Management's Harmony Biosciences position peaked at $2K in Q1 2022.
  • 183 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2022.

Based on Kayne Anderson Rudnick Investment Management's 13F filing for Q2 2022, filed 12 Aug 2022.